Lexaria Bioscience Corp. (NASDAQ: LEXX) specialises in DehydraTECH, a formulation and processing platform that enhances oral delivery of drugs, and it now holds 50 granted patents with additional applications pending worldwide. Recent pre-clinical work showed the technology produced higher brain levels of semaglutide in rodents than conventional formulations, and the company has finished dosing in a Phase 1b GLP-1 study in Australia that examines DehydraTECH-semaglutide and DehydraTECH-tirzepatide. The stock has gained roughly 23 % over the past week and has posted strong three-month performance, signalling growing investor interest. To maintain progress, Lexaria arranged a new equity financing (gross proceeds about $4 million) that it will direct toward working capital and general corporate purposes. Earlier this year the firm terminated a “Capital on Demand” at-the-market programme with JonesTrading after raising only $38,236, underscoring its need for alternative funding sources. The company continues to focus on advancing its clinical pipeline, broadening its patent estate, and exploring additional applications for DehydraTECH across multiple therapeutic categories.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2025